Radiochemicals for research and clinical use

BV Cyclotron VU is a global health science company that produces radiopharmaceuticals and radiochemicals for medical diagnostics and research. Located at the campus of VU University Medical Center in Amsterdam, Cyclotron VU produces GMP- compliant medical isotopes in state-of-the-art manufacturing facilities. These products are used daily by pharmaceutical and biotechnology companies, medical device manufacturers, hospitals, clinics, and research laboratories.

Everolimus decreases the uptake of 89Zr-bevacizumab by neuroendocrine tumors

5/7/2014: In a joint effort, researchers from various departments at the University of Groningen, the Netherlands, have recently shown that everolimus, a drug currently used in the treatment of diverse cancer types, reduces the uptake of 89Zr-labeled bevacizumab in patients with neuroendocrine tumors. arrow

Study harmonizes 89Zr-PET/CT performance in multicenter studies

13/2/2014: Researchers from the Medical Center of the VU University, Amsterdam, have recently carried out a multicenter evaluation to make the performance of PET/CT procedures using 89Zr uniform across different sites. Their positive results have just been published in the Journal of Nuclear Medicine. arrow

BV Cyclotron to produce 18F-NeuraCeq ™ for the Dutch market in cooperation with Piramal and IBA Molecular

23/1/2014: Piramal Imaging SA has recently announced the recommended approval of its investigational imaging agent NeuraCeq ™ (Florbetaben 18F) in the EU. For the Dutch market, BV Cyclotron will produce18F-NeuraCeq ™ in cooperation with Piramal and IBA Molecular. arrow

Upcoming Webinar: Advancing Discovery and Development of Biologics Through Non-Invasive Biodistribution Imaging

6/9/2013: On Tuesday, September 10, 2013, Dr. Maria Vosjan of BV Cyclotron VU, among others, will be a guest speaker at the Webinar Advancing Discovery and Development of Biologics Through Non-Invasive Biodistribution Imaging, hosted by Molecular Imaging, Inc. arrow

ARTFORCE - 1 Million Euro granted for production and delivery of 89Zr-radiolabeled antibodies

2/8/2013: Last week, researchers at the VU University Medical Center (VUmc) in Amsterdam received a 1-million Euro funding for a multicenter trial in head and neck cancer patients. The funding, granted by KWF/Alpe d’HuZes, will be used by the VUmc to produce 89Zr-radiolabeled antibodies for leading oncological centers in Europe. arrow